## Polymyositis

Neurology 61, 316-321

DOI: 10.1212/wnl.61.3.316

Citation Report

#	Article	IF	CITATIONS
1	Idiopathic inflammatory myopathies: A treatment update. Current Rheumatology Reports, 2003, 5, 431-436.	2.1	24
2	Unicorns, dragons, polymyositis, and other mythological beasts. Neurology, 2003, 61, 288-289.	1.5	113
3	Unicorns, dragons, polymyositis, and other mythical beasts. Neurology, 2004, 63, 403-404.	1.5	2
4	Polymyositis. Archives of Neurology, 2004, 61, 132.	4.9	27
5	Genes, trials, and care: the dynamics of neuromuscular disease. Lancet Neurology, The, 2004, 3, 16.	4.9	4
6	Adult inflammatory myopathies. Best Practice and Research in Clinical Rheumatology, 2004, 18, 331-344.	1.4	43
7	The future prospects in the classification, diagnosis and therapies of inflammatory myopathies: A view to the future from the ?bench-to-bedside?. Journal of Neurology, 2004, 251, 651-7.	1.8	9
8	Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clinical Rheumatology, 2004, 23, 262-265.	1.0	16
11	Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?. Current Opinion in Rheumatology, 2004, 16, 707-713.	2.0	24
12	Is it really myositis? A consideration of the differential diagnosis. Current Opinion in Rheumatology, 2004, 16, 684-691.	2.0	41
14	Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Current Opinion in Neurology, 2004, 17, 561-567.	1.8	100
15	Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ: British Medical Journal, 2004, 329, 1464-1467.	2.4	25
16	Polymyositis: An overdiagnosed entity. Neurology, 2004, 63, 402-403.	1.5	27
17	Advances in Diagnosis and Management of Inflammatory Myopathies. Journal of Clinical Neuromuscular Disease, 2005, 6, 167-179.	0.3	2
18	Procedures related to connective tissue disease. Best Practice and Research in Clinical Rheumatology, 2005, 19, 417-436.	1.4	3
19	Amyloid myopathy: Characteristic features of a still underdiagnosed disease. Muscle and Nerve, 2005, 31, 266-272.	1.0	72
20	Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle and Nerve, 2005, 32, 247-260.	1.0	96
21	Imaging and skeletal muscle disease. Current Rheumatology Reports, 2005, 7, 106-114.	2.1	31

#	ARTICLE	IF	CITATIONS
23	Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies. Medicine (United States), 2005, 84, 231-249.	0.4	416
24	Muscle Involvement in Mixed Connective Tissue Disease. Rheumatic Disease Clinics of North America, 2005, 31, 509-517.	0.8	21
25	Preservation of in vitro muscle fiber function in dermatomyositis and inclusion body myositis: a single fiber study. Neuromuscular Disorders, 2005, 15, 349-354.	0.3	11
26	Paediatric Idiopathic Inflammatory Muscle Disease. Drugs, 2005, 65, 1355-1365.	4.9	36
28	An unusual pathologic feature associated with dermatomyositis. Neuromuscular Disorders, 2006, 16, 391-393.	0.3	1
29	Polymyositis and Dermatomyositis. , 2006, , 453-463.		3
30	INFLAMMATORY MYOPATHIES. CONTINUUM Lifelong Learning in Neurology, 2006, 12, 140-168.	0.4	0
31	Advances in the therapy of idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2006, 18, 236-241.	2.0	13
32	Epidemiology of neuroimmunological diseases. Journal of Neurology, 2006, 253, v2-v8.	1.8	62
33	Differential diagnosis of idiopathic inflammatory myopathies. Current Rheumatology Reports, 2006, 8, 178-187.	2.1	23
34	Myositis specific autoantibodies. Current Rheumatology Reports, 2006, 8, 196-203.	2.1	74
35	Brachio-cervical inflammatory myopathies: Clinical, immune, and myopathologic features. Arthritis and Rheumatism, 2006, 54, 1687-1696.	6.7	30
37	Expression of granulysin in polymyositis and inclusion-body myositis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1187-1190.	0.9	24
38	Long-term outcome in polymyositis and dermatomyositis. Annals of the Rheumatic Diseases, 2006, 65, 1456-1461.	0.5	215
39	Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology, 2007, 69, 2008-2019.	1.5	102
40	MYOSITIS AUTOANTIBODIES: AMINOACYL-tRNA SYNTHETASE, SIGNAL RECOGNITION PARTICLE, Mi-2, AND PM-Scl AUTOANTIBODIES., 2007,, 577-589.		0
41	Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Annals of the Rheumatic Diseases, 2007, 67, 614-619.	0.5	36
43	Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Research and Therapy, 2007, 9, R78.	1.6	167

#	ARTICLE	IF	Citations
44	Inclusion body myositis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 86, 255-272.	1.0	22
47	Myopathy associated with gluten sensitivity. Muscle and Nerve, 2007, 35, 443-450.	1.0	63
48	Prognosis of polymyositis and dermatomyositis. Clinical Rheumatology, 2007, 26, 92-92.	1.0	1
49	Actualités desÂmyopathies inflammatoires: nouvelles classifications, critères diagnostiques, histopathologie, etÂtraitements. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 774-782.	0.0	1
50	Tubuloreticular Structures in Different Types of Myositis: Implications for Pathogenesis. Ultrastructural Pathology, 2008, 32, 123-126.	0.4	29
51	Inflammatory Myopathies. Dermatomyositis, Polymyositis, and Inclusion Body Myositis. ReumatologÃa ClÃnica (English Edition), 2008, 4, 197-206.	0.2	3
52	Miopatie infiammatorie. EMC - Neurologia, 2008, 8, 1-23.	0.0	0
55	A Man with Muscle Pains. , 2008, , 567-571.		0
56	Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology, 2008, 47, 1539-1542.	0.9	65
57	Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology, 2008, 70, 418-424.	1.5	212
58	Inflammatory Myopathies: Evaluation and Management. Seminars in Neurology, 2008, 28, 241-249.	0.5	64
59	Using immunoglobulins in muscular disease treatment. Expert Opinion on Biological Therapy, 2008, 8, 1143-1150.	1.4	5
60	Understanding the idiopathic inflammatory myopathies. JAAPA: Official Journal of the American Academy of Physician Assistants, 2008, 21, 42-48.	0.1	1
61	Polymyositis. Neurology, 2008, 70, 414-415.	1.5	9
63	Steroid-Responsive Myopathy: Immune-Mediated Necrotizing Myopathy or Polymyositis Without Inflammation?. Journal of Clinical Neuromuscular Disease, 2008, 9, 341-344.	0.3	18
64	Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opinion on Pharmacotherapy, 2009, 10, 1183-1190.	0.9	47
65	The Inflammatory Myopathies. , 2009, , .		4
66	Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USA. Journal of Rheumatology, 2009, 36, 2704-2710.	1.0	77

#	ARTICLE	IF	Citations
67	Inclusion body myositis: old and new concepts. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1186-1193.	0.9	98
68	Idiopathic Inflammatory Myopathies. Frontiers of Neurology and Neuroscience, 2009, 26, 126-146.	3.0	15
69	How to perform and analyse biopsies in relation to connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2009, 23, 233-255.	1.4	8
70	Association of the leukocyte immunoglobulin G (Fcl̂³) receptor IIIaâ€158V/F polymorphism with inflammatory myopathies in Dutch patients. Tissue Antigens, 2009, 73, 586-589.	1.0	5
72	Evaluation and treatment of inflammatory myopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1060-1068.	0.9	162
73	Role of Regulatory T Cells in a New Mouse Model of Experimental Autoimmune Myositis. American Journal of Pathology, 2009, 174, 989-998.	1.9	74
75	Development of Classic Dermatomyositis Rash Years After Diagnosis of Juvenile Polymyositis. Journal of Clinical Rheumatology, 2009, 15, 316-318.	0.5	3
76	Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2010, 22, 623-626.	2.0	22
77	7. Polymyositis (PM) and Dermatomyositis (DM) The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1795-1802.	0.0	0
79	Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases. Annals of Indian Academy of Neurology, 2010, 13, 250.	0.2	11
80	Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscular Disorders, 2010, 20, 382-389.	0.3	79
81	Polymyositis in African HIV-infected subjects. Neuromuscular Disorders, 2010, 20, 735-739.	0.3	25
82	CD8/MHC-I Complex is Specific but Not Sensitive for the Diagnosis of Polymyositis. Journal of International Medical Research, 2010, 38, 1049-1059.	0.4	6
84	Observations on the classification of the inflammatory myopathies. Presse Medicale, 2011, 40, e199-e208.	0.8	20
85	Histopathological differences between human T-lymphotropic virus type 1-positive and human T-lymphotropic virus type 1-negative polymyositis. Clinical and Experimental Neuroimmunology, 2011, 2, 12-24.	0.5	4
86	MiopatÃas inflamatorias. MiopatÃas metabólicas y tóxicas. Medicine, 2011, 10, 5272-5282.	0.0	0
87	Gastrointestinal Complications of Neuromuscular Disorders., 2011,, 51-60.		0
88	Necrotizing autoimmune myopathy. Current Opinion in Rheumatology, 2011, 23, 612-619.	2.0	118

#	Article	IF	Citations
89	Acquired immune and inflammatory myopathies. Current Opinion in Rheumatology, 2011, 23, 595-604.	2.0	121
90	Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurologica Scandinavica, 2011, 123, 122-129.	1.0	23
91	Idiopathic inflammatory myopathies. Journal of Neuroimmunology, 2011, 231, 32-42.	1.1	47
92	Polymyositis associated with hypothyroidism or hyperthyroidism: two cases and review of the literature. Clinical Rheumatology, 2011, 30, 449-458.	1.0	11
95	Idiopathic Inflammatory Myopathies. Seminars in Neurology, 2012, 32, 227-236.	0.5	37
98	Immune-Mediated Necrotizing Myopathy Is Characterized by a Specific Th1-M1 Polarized Immune Profile. American Journal of Pathology, 2012, 181, 2161-2171.	1.9	102
100	Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle and Nerve, 2012, 45, 676-683.	1.0	127
101	Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30â€year epidemiologic study of histologyâ€proven cases. International Journal of Rheumatic Diseases, 2013, 16, 331-338.	0.9	65
102	Clinical aspects of autoimmune rheumatic diseases. Lancet, The, 2013, 382, 797-808.	6.3	195
103	Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies. Journal of Rheumatology, 2013, 40, 550-564.	1.0	82
104	Cutaneous ulceration: more than skin deep?. Clinical and Experimental Dermatology, 2013, 38, 443-445.	0.6	1
105	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
106	Editorial: The efficacy of rituximab in refractory myositis: The jury is still out. Arthritis and Rheumatism, 2013, 65, 303-306.	6.7	22
108	Classification and Diagnostic Investigation in Inflammatory Myopathies: A Study of 99 Patients. Journal of Rheumatology, 2013, 40, 1173-1182.	1.0	13
109	When and how to perform biopsies in a patient with a (suspected) connective tissue disease. Best Practice and Research in Clinical Rheumatology, 2013, 27, 209-236.	1.4	3
110	MRI in Inflammatory Myopathies and Autoimmune-Mediated Myositis. Medical Radiology, 2013, , 255-269.	0.0	0
112	Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies. Medicine (United States), 2013, 92, 15-24.	0.4	42
113	Beneficial Role of Rapamycin in Experimental Autoimmune Myositis. PLoS ONE, 2013, 8, e74450.	1.1	27

#	Article	IF	CITATIONS
114	Neuromuscular Complications of General Medical Disorders. , 2014, , 1209-1242.		0
115	Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Research and Therapy, 2014, 16, R39.	1.6	57
116	Idiopathic inflammatory myopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 495-512.	1.0	21
118	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmunity Reviews, 2014, 13, 367-371.	2.5	233
119	Idiopathic Inflammatory Myopathies. Neurologic Clinics, 2014, 32, 595-628.	0.8	82
120	Predictors of Clinical Improvement in Rituximabâ€Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	2.9	210
121	Long-term follow-up of 62 patients with myositis. Journal of Neurology, 2014, 261, 992-998.	1.8	55
122	Neurology of Rheumatologic Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 456.	2.0	10
123	Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?. Current Rheumatology Reports, 2014, 16, 433.	2.1	19
125	<scp>SLE</scp> myopathy: a clinicopathological study. International Journal of Rheumatic Diseases, 2015, 18, 886-891.	0.9	26
126	Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases. Journal of Neuromuscular Diseases, 2015, 2, 13-25.	1.1	9
127	Paraneoplastic necrotizing myopathy in association with metastatic malignant melanoma: two case reports and a review of the literature. Case Reports in Clinical Pathology, 2015, 2, .	0.0	0
128	Meeting the challenges in the diagnosis of inflammatory myopathies. South African Medical Journal, 2015, 105, 1076.	0.2	4
129	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e172.	3.1	38
130	An overview of polymyositis and dermatomyositis. Muscle and Nerve, 2015, 51, 638-656.	1.0	176
131	Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatology International, 2015, 35, 915-920.	1.5	32
132	Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscular Disorders, 2015, 25, 451-456.	0.3	24
135	Respiratory failure as presenting symptom of necrotizing autoimmune myopathy with anti-melanoma differentiation-associated gene 5 antibodies. Neuromuscular Disorders, 2015, 25, 457-460.	0.3	7

#	Article	IF	Citations
136	The Clinical Spectrum of Necrotizing Autoimmune Myopathy. JAMA Neurology, 2015, 72, 977.	4.5	1
137	Enfermedades de los músculos y de la unión neuromuscular. Medicine, 2015, 11, 4495-4503.	0.0	0
138	Inflammatory Muscle Diseases. New England Journal of Medicine, 2015, 372, 1734-1747.	13.9	559
139	Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathologica, 2015, 129, 611-624.	3.9	112
140	Statin induced necrotizing autoimmune myopathy. Journal of the Neurological Sciences, 2015, 351, 13-17.	0.3	35
141	Inflammation induced loss of skeletal muscle. Bone, 2015, 80, 131-142.	1.4	205
142	Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 622-632.	1.8	60
143	Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology, 2015, 54, 50-63.	0.9	248
144	Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Frontiers in Neurology, 2016, 7, 64.	1.1	106
145	Autoimmune Myopathies: Where Do We Stand?. Frontiers in Immunology, 2016, 7, 234.	2.2	20
146	Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 2016, 29, 662-673.	1.8	96
147	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.3	19
149	Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1038-1044.	0.9	229
150	Diagnosis and classification of idiopathic inflammatory myopathies. Journal of Internal Medicine, 2016, 280, 39-51.	2.7	134
151	Leitlinie Dermatomyositis – Auszug aus der interdisziplinÃren S2kâ€Leitlinie zu Myositissyndromen der deutschen Gesellschaft für Neurologie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.4	0
152	A case report of autoimmune necrotizing myositis presenting as dysphagia and neck swelling. BMC Ear, Nose and Throat Disorders, 2016, 16, 7.	2.6	4
153	Amyopathic Dermatomyositis: A Concise Review of Clinical Manifestations and Associated Malignancies. American Journal of Clinical Dermatology, 2016, 17, 509-518.	3.3	33
154	Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG - Journal of the German Society of Dermatology, 2016, 14, 321-338.	0.4	43

#	ARTICLE	IF	Citations
155	Integrated classification of inflammatory myopathies. Neuropathology and Applied Neurobiology, 2017, 43, 62-81.	1.8	92
156	Diagnosis and Management of Immune-Mediated Myopathies. Mayo Clinic Proceedings, 2017, 92, 826-837.	1.4	60
157	Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology. Autoimmunity Reviews, 2017, 16, 693-700.	2.5	52
158	Immune and myodegenerative pathomechanisms in inclusion body myositis. Annals of Clinical and Translational Neurology, 2017, 4, 422-445.	1.7	41
159	MiopatÃas inflamatorias. Medicine, 2017, 12, 1679-1689.	0.0	0
160	Editorial: A New Classification of Adult Autoimmune Myositis. Arthritis and Rheumatology, 2017, 69, 878-884.	2.9	81
161	Sarcoplasmic MxA expression. Neurology, 2017, 88, 493-500.	1.5	118
162	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
163	Diagnosis of dermatomyositis: Autoantibody profile and muscle pathology. Clinical and Experimental Neuroimmunology, 2017, 8, 302-312.	0.5	7
164	Paraneoplastic Necrotizing Autoimmune Myopathy in a Patient Undergoing Laparoscopic Pancreatoduodenectomy for Distal Cholangiocarcinoma. Case Reports in Gastroenterology, 2017, 10, 525-530.	0.3	4
165	Atorvastatin-induced necrotizing autoimmune myositis. Medicine (United States), 2017, 96, e5694.	0.4	27
166	Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology, 2017, 89, 1060-1068.	1.5	29
167	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 327-335.	1.1	8
168	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
169	Increased prevalence of celiac disease in idiopathic inflammatory myopathies. Brain and Behavior, 2017, 7, e00803.	1.0	11
170	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391
171	Immune-mediated Necrotizing Myopathy (IMNM) and HLA Polymorphisms. Major Histocompatibility Complex, 2017, 24, 46-53.	0.2	0
172	Current diagnosis and treatment of polymyositis and dermatomyositis. Modern Rheumatology, 2018, 28, 913-921.	0.9	82

#	Article	IF	CITATIONS
173	Classification of myositis. Nature Reviews Rheumatology, 2018, 14, 269-278.	<b>3.</b> 5	210
174	Idiopathic Inflammatory Myopathies. , 2018, , 113-130.		0
175	New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. Current Rheumatology Reports, 2018, 20, 18.	2.1	65
176	Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2018, 77, 720-727.	0.5	42
177	Myositis an evolving spectrum of disease. Immunological Medicine, 2018, 41, 46-54.	1.4	14
178	Muscle Magnetic Resonance Imaging for the Differentiation of Multiple Acyl-CoA Dehydrogenase Deficiency and Immune-mediated Necrotizing Myopathy. Chinese Medical Journal, 2018, 131, 144-150.	0.9	15
179	MiopatÃas inflamatorias. Revista Médica ClÃnica Las Condes, 2018, 29, 611-621.	0.2	2
181	Histopathology of the muscle in rheumatic diseases. Reumatismo, 2018, 70, 133-145.	0.4	3
182	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology, 2018, 75, 1528.	4.5	301
183	A rare cause of proximal muscle weakness: immune necrotising myopathy. Scottish Medical Journal, 2018, 63, 82-86.	0.7	0
184	Autoimmune Muskelerkrankungen. , 2018, , 149-157.		1
185	Current Classification and Management of Inflammatory Myopathies. Journal of Neuromuscular Diseases, 2018, 5, 109-129.	1.1	190
186	Classification and management of adult inflammatory myopathies. Lancet Neurology, The, 2018, 17, 816-828.	4.9	267
187	Polymyositis and dermatomyositis – challenges in diagnosis and management. Journal of Translational Autoimmunity, 2019, 2, 100018.	2.0	44
188	Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study. Clinical Rheumatology, 2019, 38, 3459-3469.	1.0	6
189	How to investigate: Suspected systemic rheumatic diseases in patients presenting with muscle complaints. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101437.	1.4	3
190	Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. European Journal of Neurology, 2019, 26, 1494-1496.	1.7	3
191	Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR/ACR in Chinese patients. International Journal of Rheumatic Diseases, 2019, 22, 1278-1282.	0.9	15

#	Article	IF	Citations
194	Immune-mediated necrotising myopathy: A critical review of current concepts. Seminars in Arthritis and Rheumatism, 2019, 49, 420-429.	1.6	45
195	Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clinical Rheumatology, 2019, 38, 1931-1934.	1.0	18
196	Inclusion body myositis: clinical features and pathogenesis. Nature Reviews Rheumatology, 2019, 15, 257-272.	3.5	163
197	Take two: Utility of the repeat skeletal muscle biopsy. Muscle and Nerve, 2019, 60, 41-46.	1.0	3
198	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Annals of the Rheumatic Diseases, 2019, 78, 657-662.	0.5	24
199	Cancer and Idiopathic Inflammatory Myositis. Current Treatment Options in Rheumatology, 2019, 5, 231-241.	0.6	2
200	Inflammatory myopathy with myasthenia gravis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e535.	3.1	33
201	Whole-body MRI and pathological findings in adult patients with myopathies. Skeletal Radiology, 2019, 48, 653-676.	1.2	21
202	A pattern-based approach to the interpretation of skeletal muscle biopsies. Modern Pathology, 2019, 32, 462-483.	2.9	14
203	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology, 2019, 58, 468-475.	0.9	22
204	Inflammatory Myopathies. , 2019, , 131-163.		0
205	Needle electromyography, muscle MRI, and muscle pathology: Correlations in idiopathic inflammatory myopathies. Neurology and Clinical Neuroscience, 2020, 8, 28-35.	0.2	1
206	Inflammatory Muscle Diseases. , 0, , .		1
209	Immune and Inflammatory Myopathies. , 2021, , 321-345.		0
210	Dysphagia in adult myopathies. Neuromuscular Disorders, 2021, 31, 5-20.	0.3	13
211	Clinical utility of antiâ€cytosolic 5'â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	1.7	18
212	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology, 2021, 60, 2615-2628.	0.9	69
213	Évolution des critères diagnostiques des myopathies inflammatoires. Pratique Neurologique - FMC, 2021, 12, 64-68.	0.1	0

#	Article	IF	Citations
214	Anti-HMGCR myopathy misdiagnosed as motor neuron disease and complicated with COVID-19 infection. Neurological Sciences, 2021, 42, 1679-1682.	0.9	5
215	Epidemiological characterization of patients with inflammatory myopathy in a fourth level hospital in Cali, Colombia. Revista Colombiana De ReumatologÃa (English Edition), 2021, 28, 83-88.	0.1	O
217	Recent data and developments in myositis. Brain Pathology, 2021, 31, e12966.	2.1	1
219	A 60-Year-Old Man With Dyspnea, Proximal Muscle Weakness, and Pulmonary Arterial Hypertension. Chest, 2021, 160, e225-e231.	0.4	0
220	Skeletal muscle immunohistochemistry of acquired and hereditary myopathies. Current Opinion in Rheumatology, 2021, 33, 529-536.	2.0	2
222	Polymyositis: does it really exist as a distinct clinical subset?. Current Opinion in Rheumatology, 2021, 33, 537-543.	2.0	13
223	Resolution of shawl sign in dermatomyositis using pulsed dye laser. JAAD Case Reports, 2021, 16, 74-76.	0.4	1
224	Gastrointestinal Complications of Neuromuscular Disorders. , 2022, , 79-96.		0
225	Palliative Care in Patients with Neuromuscular Diseases. Respiratory Medicine, 2021, , 231-253.	0.1	0
226	Idiopathic inflammatory myopathies - new advances. Neurologie Pro Praxi, 2021, 21, 477-484.	0.0	0
227	Anti N1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis. Muscle and Nerve, 2021, 63, 490-496.	1.0	19
228	Neuromuscular Complications of General Medical Disorders. , 2008, , 1123-1156.		1
229	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology, 2021, 60, 3398-3403.	0.9	27
230	Altered Lipid Levels in Untreated Patients with Early Polymyositis. PLoS ONE, 2014, 9, e89827.	1.1	16
231	Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS ONE, 2016, 11, e0160753.	1.1	29
232	Clinical Characteristics, Treatment, and Outcomes in Patients with Idiopathic Inflammatory Myopathy Concomitant with Heart Failure. International Heart Journal, 2020, 61, 1005-1013.	0.5	4
233	The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies. Open Rheumatology Journal, 2016, 10, 141-149.	0.1	5
234	Diagnosis and Clinical Development of Sporadic Inclusion Body Myositis and Polymyositis With Mitochondrial Pathology: A Single-Center Retrospective Analysis. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1060-1067.	0.9	5

#	Article	IF	CITATIONS
235	The Clinical and Pathological Characteristics of Polymyositis Using ENMC Diagnostic Criteria. The Journal of the Korean Rheumatism Association, 2008, 15, 296.	0.1	0
236	Clinical features, classification, and epidemiology of inflammatory muscle disease. , 2011, , 1439-1455.e4.		1
238	Die entzündlichen Myopathien – autoimmun bedingte Myositiden. , 2012, , 153-163.		0
240	Muscle disease and myasthenia in pregnancy. Series in Maternal-fetal Medicine, 2012, , 249-252.	0.1	0
241	Dystrophies and Myopathies (Including Oculopharyngeal). , 2013, , 421-429.		0
243	Polymyositis Associated with Autoimmune Hepatitis. Journal of the Korean Neurological Association, 2017, 35, 208-210.	0.0	0
245	Myositis. Contemporary Clinical Neuroscience, 2019, , 787-808.	0.3	0
246	Weichteilrheumatismus (extraartikulÃ <b>r</b> er Rheumatismus) und seine Differenzialdiagnose. , 2019, , 309-362.		0
248	Recurrent focal myositis developing into a generalised idiopathic inflammatory myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies. BMJ Case Reports, 2019, 12, e229787.	0.2	1
249	Making the Diagnosis of Myositis: Muscle Biopsy and Interpretation. , 2020, , 109-124.		0
251	İnflamatuar miyozitler: İdiyopatik mi? Çakışma mı? Paraneoplastik mi?. Ege Tıp Dergisi, 0, , 51-57.	0.1	0
254	The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clinical and Experimental Rheumatology, 2013, 31, 128-34.	0.4	30
256	Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 219-240.	2.7	6
257	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86.	18.1	212
258	5. Classification of Myositis and Disease Concept-recent Advances The Journal of the Japanese Society of Internal Medicine, 2021, 110, 481-485.	0.0	0
260	Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy. Journal of Neuroimmunology, 2022, 365, 577833.	1.1	5
261	Myositis-specific antibodies: Overview and clinical utilization. Rheumatology and Immunology Research, 2022, 3, 1-10.	0.2	11
262	Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. International Journal of Molecular Sciences, 2022, 23, 4301.	1.8	16

#	Article	IF	CITATIONS
263	Advances in neuromuscular disease 2003: the year in review. Journal of Clinical Neuromuscular Disease, 2004, 5, 169-75.	0.3	О
265	Autoimmune diseases in different organs. , 2022, , 1-13.		O
266	Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. BMC Musculoskeletal Disorders, 2022, 23, 425.	0.8	6
267	Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review. BMC Medical Genomics, 2022, 15, .	0.7	7
268	Is it really myositis? Mimics and pitfalls. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101764.	1.4	5
269	Emergencies in Idiopathic Inflammatory Myopathies. , 2022, , 283-317.		0
270	Inflammatory Myopathies. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1643-1662.	0.4	0
271	MYOSITIS WITH PROMINENT B CELL AGGREGATES MAY MEET CLASSIFICATION CRITERIA FOR SPORADIC INCLUSION BODY MYOSITIS. Neuromuscular Disorders, 2022, , .	0.3	0
272	Current Concepts and Future Prospects in Immune-Mediated Myopathies., 2023,, 161-189.		0
273	Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review. Frontiers in Medicine, $0,10,.$	1.2	3
274	Incorporating circulating cytokines into the idiopathic inflammatory myopathy subclassification toolkit. Frontiers in Medicine, 0, $10$ , .	1.2	0
275	Paraneoplastic Necrotizing Myopathy Associated With Metastatic Colon Cancer: A Case Report. Cureus, 2023, , .	0.2	0
282	Axial Myopathies., 2024,,.		0